Confronting 
neurodegeneration

To improve the lives of patients and their families.

To provide medicines that slow, stop, or revert the progression.

By targeting the pathology of toxic misfolded proteins.

Our Programs

Structured for Success

Based in the biotech hub of San Diego, our in-house expertise of our people and global collaborations with academic and industry partners allow us to discover novel therapeutic targets and develop innovative therapeutics.  


About Our Team

News

Neuropore Therapies (NPT) Announces Achievement of Key Program Milestone September 13, 2016

Based on promising findings from ongoing clinical and non-clinical studies, UCB awarded NPT a major program milestone of $5 million.


See All News

NPTTM Publications

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies July 2016

Report in Scientific Reports, describes the use of non-invasive retinal imaging in animal models as a tool to monitor the fate of α-synuclein accumulation in the CNS.

See All Publications

Our Major Partnerships

Ever Neuro Pharma
The Michael J. Fox Foundation for Parkinson's Research
UCB
Neuropore Video

Our Technology

Learn about Neuropore’s two part development strategy targeting misfolded proteins -- the key pathological culprit(s) underlying neurodegenerative disorders.

Learn More See All Videos